4/4
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Neutral
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4/2
07:00 am
sndx
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
Medium
Report
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
4/2
02:09 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was upgraded by analysts at StockNews.com to a "sell" rating.
3/20
11:06 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $39.00 to $41.00. They now have an "overweight" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $39.00 to $41.00. They now have an "overweight" rating on the stock.
3/5
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/5
10:07 am
sndx
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... [Yahoo! Finance]
3/4
12:47 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $35.00 to $39.00. They now have an "overweight" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $35.00 to $39.00. They now have an "overweight" rating on the stock.
3/4
12:28 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target lowered by analysts at Citigroup Inc. from $45.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target lowered by analysts at Citigroup Inc. from $45.00 to $42.00. They now have a "buy" rating on the stock.
3/4
08:03 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
3/3
07:42 am
sndx
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
3/3
07:01 am
sndx
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Low
Report
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2/25
07:00 am
sndx
Syndax Announces Participation in March Investor Conferences
Low
Report
Syndax Announces Participation in March Investor Conferences
2/24
07:00 am
sndx
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
Medium
Report
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
2/20
07:17 pm
sndx
Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation [Yahoo! Finance]
2/10
05:42 pm
sndx
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
2/4
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/30
07:00 am
sndx
Syndax Announces Participation in February Investor Conferences
Low
Report
Syndax Announces Participation in February Investor Conferences
1/15
05:34 pm
sndx
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Neutral
Report
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
1/13
07:00 am
sndx
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
1/8
08:56 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target lowered by analysts at Scotiabank from $18.00 to $16.00. They now have a "sector perform" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target lowered by analysts at Scotiabank from $18.00 to $16.00. They now have a "sector perform" rating on the stock.
1/7
09:20 pm
sndx
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
1/7
07:25 am
sndx
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/7
07:00 am
sndx
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
1/3
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)